Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)

EGX:RMDA Revenue

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) had revenue of 865.62M EGP in the quarter ending March 31, 2025, with 89.73% growth. This brings the company's revenue in the last twelve months to 3.18B, up 59.98% year-over-year. In the year 2024, Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) had annual revenue of 2.77B with 44.03% growth.

• Revenue (ttm): 3.18B
• Revenue Growth: +59.98%
• P/S Ratio: 2.18
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 6.92B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	2.77B	846.34M	44.03%
Dec 31, 2023	1.92B	438.40M	29.54%
Dec 31, 2022	1.48B	237.52M	19.06%
Dec 31, 2021	1.25B	286.27M	29.81%
Dec 31, 2020	960.17M	66.20M	7.41%